User profiles for M. Fujii

Minoru Fujii (藤井 稔)

- M. Fujii - Verified email at eedept.kobe-u.ac.jp - Cited by 16590

Manabu Fujii

- Verified email at m.titech.ac.jp - Cited by 4571

Management of gastric cancer in Asia: resource-stratified guidelines

…, T Sano, HK Yang, X Zhang, SR Park, M Fujii… - The Lancet …, 2013 - thelancet.com
Gastric cancer is the fourth most common cancer globally, and is the second most common
cause of death from cancer worldwide. About three-quarters of newly diagnosed cases in …

Early brain injury, an evolving frontier in subarachnoid hemorrhage research

M Fujii, J Yan, WB Rolland, Y Soejima, B Caner… - Translational stroke …, 2013 - Springer
Subarachnoid hemorrhage (SAH), predominantly caused by a ruptured aneurysm, is a
devastating neurological disease that has a morbidity and mortality rate higher than 50 %. Most of …

Photodegradation of pharmaceuticals and personal care products in water treatment using carbonaceous-TiO2 composites: A critical review of recent literature

D Awfa, M Ateia, M Fujii, MS Johnson, C Yoshimura - Water research, 2018 - Elsevier
The high concentrations of pharmaceuticals and personal care products (PPCP) that found
in water in many locations are of concern. Among the available water treatment methods, …

[HTML][HTML] Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

…, T Yamaguchi, T Kinoshita, M Fujii… - … England Journal of …, 2007 - Mass Medical Soc
… 1.25 m 2 received 80 mg daily; those with a body-surface area of 1.25 m 2 or more but less
than 1.5 m 2 received 100 mg daily; and those with a body-surface area of 1.5 m 2 or more …

[HTML][HTML] Mammalian thioredoxin is a direct inhibitor of apoptosis signal‐regulating kinase (ASK) 1

M Saitoh, H Nishitoh, M Fujii, K Takeda… - The EMBO …, 1998 - embopress.org
… staining (M.Fujii and H.Ichijo, unpublished observation). The comparable level of protein
expression for each ASK1 construct was determined by immunoprecipitation (data not shown). …

[PDF][PDF] Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer

…, H Furukawa, T Yamaguchi, A Nashimoto, M Fujii… - J clin …, 2011 - researchgate.net
Purpose The first planned interim analysis (median follow-up, 3 years) of the Adjuvant
Chemotherapy Trial of S-1 for Gastric Cancer confirmed that the oral fluoropyrimidine derivative S-…

Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein.

…, F Tanabe, K Konishi, M Micallef, M Fujii… - … (Baltimore, Md.: 1950 …, 1996 - journals.aai.org
We have recently reported that a novel molecule, murine IFN-gamma-inducing factor (IGIF)
produced by mouse liver cells, possesses potent biologic activities, including the induction of …

Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids

M Matano, S Date, M Shimokawa, A Takano, M Fujii… - Nature medicine, 2015 - nature.com
Human colorectal tumors bear recurrent mutations in genes encoding proteins operative in
the WNT, MAPK, TGF-β, TP53 and PI3K pathways 1 , 2 . Although these pathways influence …

Interferon‐γ‐inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin‐12 for interferon‐γ production

…, M Fujii, M Ikeda, S Fukuda, M Kurimoto - European journal of …, 1996 - Wiley Online Library
The novel cytokine interferon‐γ‐inducing factor (IGIF) augments natural killer (NK) cell
activity in cultures of human peripheral blood mononuclear cells (PBMC), similarly to the …

Measuring the thermal conductivity of a single carbon nanotube

M Fujii, X Zhang, H Xie, H Ago, K Takahashi, T Ikuta… - Physical review …, 2005 - APS
… 3–5:7 m in length, respectively. The gap between the nanofilm and substrate is 6 m. The CNTs
made … 1(b)] are 40.0 nm, 362 nm, and 5:67 m, respectively. The diameter and length of the …